

## Rhythm Biosciences Establishes Internationally Renowned Clinical Advisory Board

### Highlights

- ✓ Rhythm engages world-class specialists in the Colorectal Cancer screening and early diagnosis areas;
- ✓ Appointment of the Clinical Advisory Board (CAB) will provide expert guidance and oversight throughout the further development process of the ColoSTAT® test kit; and
- ✓ The CAB will support Rhythm to ensure the accuracy, safety, and efficacy of the test, as well as its relevance in the clinical practice and towards better patient experience and care.

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (“**Rhythm**” or the “**Company**”), whose initial mission is to deliver a test to detect Colorectal Cancer early, is pleased to announce the establishment of its Clinical Advisory Board (CAB), bringing world-class expertise and guidance on scientific, clinical, and regulatory aspects for the ColoSTAT® test’s further developmental process. The CAB will advise on the critical data and outcome measures, to ensure the ColoSTAT® IVDR readiness for the company’s registration and launch in different international markets.

### Members of the Clinical Advisory Board:

**Dr Sally Benton** - *Consultant Clinical Biochemist and Clinical Lead for Clinical and Specialist Biochemistry Services at Berkshire and Surrey Pathology Services, a pathology network that serves 6 acute hospitals. Sally is also Director of the Bowel Cancer Screening South England Hub based at the Royal Surrey County Hospital, Guildford, serving a total population of about 16 million people across the South of England.*

*Sally was awarded a BSc Hon Biochemistry degree from Leeds University in 1998 and in 2000 obtained a place on the NHS Clinical Scientist training programme in the North West of England. She obtained Fellowship of the Royal College of Pathologists in 2008 and shortly after this moved to London where she took on a Consultant Clinical Biochemist position at Barts Health NHS Trust. In 2014 Sally moved to her current position in Guildford. She leads a team of research scientists, focusing on analytical aspects and clinical applications of the Faecal Immunochemical Test (FIT) and other biomarkers, supporting early diagnosis of Colorectal Cancer. Sally was on the BSG / ACP guideline group representing biochemistry. She co-chairs the World Endoscopy Organisation expert working group on FIT for Screening and is Chair of an International Federation of Clinical Chemistry working group to standardise and harmonise FIT testing.*

**Professor Jon Emery** - *Herman Professor of Primary Care Cancer Research at the University of Melbourne, and the Victorian Comprehensive Cancer Centre (VCCC) Primary Care Research and Education Lead. He is a National Health and Medical Research Council (NHMRC) Leadership Fellow, and Director of the Cancer Australia Primary Care Collaborative Cancer Clinical Trials Group (PC4).*

*Following his medical training at Cambridge and Oxford, he has had a highly successful career in academic primary care.*

**Rhythm Biosciences Ltd**  
ACN 619 459 335  
ASX: RHY

[www.rhythmbio.com](http://www.rhythmbio.com)

**Australian Registered Address**  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

**T** +61 3 8256 2880  
**E** [info@rhythmbio.com](mailto:info@rhythmbio.com)

### Directors

Otto Buttula  
Sue MacLeman

Trevor Lockett  
Louis Panaccio

Executive Chairman  
Non-Executive Independent  
Deputy Chair  
Non-Executive Director  
Non-Executive Director

*His research focuses on the application of advances in genetic medicine, primary care oncology and the development and evaluation of complex interventions including computer decision support systems, and new cancer diagnostic and screening technologies. He is currently leading several trials on early detection of risk-based cancer in primary care.*

**Prof Finlay Macrae** - Head of Colorectal Medicine and Genetics at The Royal Melbourne Hospital, he is a lead clinician in the Familial Cancer Clinic and is engaged in research into Colorectal Cancer genetics and new therapies for Inflammatory Bowel Disease (IBD).

*He trained in London with the world's leading colonoscopist at the time (St Mark's Hospital) and brought this skill to Australia and his practice.*

*Prof Macrae, in 2016 was awarded an AO (Order of Australia) for his work in genetics and genomics. He is a Master of the World Gastroenterology Organization, and Fellow of the American Gastroenterology Association and Royal College of Physicians.*

*He initiated and is Chairman of The Australian and New Zealand Gastroenterology International Training Association ([www.anzqita.org](http://www.anzqita.org)), with training programs throughout the Pacific Islands, Timor Leste and Nepal.*

Early detection of colorectal cancer is vital to improve the chance of long term survival. Developing accurate, alternative tests that may be more acceptable to some patients is important to improve colorectal cancer outcomes for all.

“We are honoured to have world-class, distinguished leaders in their field of Colorectal Cancer diagnostics form our CAB and look forward to their expertise and guidance in this significant commercialisation stage of ColoSTAT®”, commented Otto Buttula, Executive Chairman of Rhythm.

**- ENDS -**

#### **Authorisation & Additional Information**

**This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.**

**For further information contact us via [investor@rhythmbio.com](mailto:investor@rhythmbio.com) or on +61 3 8256 2880:**

<b>Mr. Otto Buttula</b> Executive Chairman	<b>Ms. Elena Deak</b> Chief Commercial Officer
---	---

#### **About Rhythm Biosciences**

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and Twitter.

**About ColoSTAT®**

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable. The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.